Ayman Kabakibi from 5180 White Emerald Dr, San Diego, CA 92130, age 58, Phone: 8587947833

Resumes

Senior Vice President, Head Of Research And Development

view source

Location:

San Diego, CA

Industry:

Biotechnology

Work:

Wugen
Senior Vice President, Head of Research and Development
Tollnine
Co-Founder
Solstice Biologics Llc 2016 - 2018
Executive Director, Head of Biology and Pharmacology
Solstice Biologics Llc 2013 - 2016
Senior Director, Head of Biology and Pharmacology
Traversa Therapeutics, Inc Feb 2010 - Mar 2012
Head of Biology and Pharmacology

Education:

University of Massachusetts 1998
Doctorates, Doctor of Philosophy, Biochemistry Northeastern University 1993
Master of Science, Masters Damascus University 1988
Bachelors, Bachelor of Science, Pharmacy University of Massachusetts Lowell

Skills:

Pharmacology
Drug Discovery
Biotechnology
Lifesciences
Biochemistry
Drug Development
Protein Chemistry
Chemistry
Molecular Biology
Assay Development
Commercialization
Cell Biology

Principal Scientist At Kalypsys

view source

Position:

Principal Scientist at Kalypsys

Location:

Greater San Diego Area

Industry:

Biotechnology

Work:

Kalypsys
Principal Scientist
Pharmacia/Pfizer Apr 1998 - Dec 2003
Senior Scientist

Education:

University of Massachusetts at Lowell 1994 - 1998
Ph.D., Biochemistry Northeastern University 1990 - 1994
MSc, Medical Technology

Us Patents

Use Of Alpha-Linolenic Acid Metabolites For Treatment Or Prevention Of Cancer
view source
US Patent:

20020010211, Jan 24, 2002
Filed:

Jul 13, 2001
Appl. No.:

09/903707
Inventors:

Mark Obukowicz - Kirkwood MO, US
Ayman Kabakibi - Creve Coeur MO, US
Susan Green - St. Ann MO, US
Lisa Olson - Richmond Heights MO, US
Julie Lindemann - El Cerrito CA, US
International Classification:

A61K031/232
A61K031/202
A61K031/16
US Classification:

514/549000, 514/560000, 514/625000
Abstract:

Cancer in a mammal can be treated or prevented by administering to a mammal in need thereof a cancer inhibiting amount of metabolite(s) of -linolenic acid, such as stearidonic acid (18:4 n-3), eicosatetraenoic acid (20:4 n-3), docosapentaenoic acid (22:5 n-3) and mixtures thereof, especially metabolites including stearidonic acid.

Methods For The Selective Modulation Of Ppar
view source
US Patent:

20070190079, Aug 16, 2007
Filed:

Mar 19, 2007
Appl. No.:

11/687949
Inventors:

Andrew Shiau - San Diego CA, US
Mark Massari - San Diego CA, US
Guy Oshiro - San Diego CA, US
Ayman Kabakibi - San Diego CA, US
James Malecha - San Diego CA, US
Stewart Noble - San Diego CA, US
Assignee:

KALYPSYS, INC. - San Diego CA
International Classification:

A61K 31/495
US Classification:

424278100, 514709000, 514255020
Abstract:

The present invention relates to methods of selective modulation of peroxisome proliferator activated receptors (PPARs) over G-protein coupled receptor 40 (GPR40), and the use of therapeutically effective amounts of compounds and pharmaceutical compositions which selectively modulate PPAR over GPR40 for the treatment of diseases in patients in need thereof. The methods disclosed herein are exceptionally useful in treating metabolic diseases whilst avoiding certain side effects common to modulators of PPAR previously disclosed in the art.

Methods For The Upregulation Of Glut4 Via Modulation Of Ppar Delta In Adipose Tissue And For The Treatment Of Disease
view source
US Patent:

20070249519, Oct 25, 2007
Filed:

Apr 19, 2007
Appl. No.:

11/737145
Inventors:

Mausumee Guha - San Diego CA, US
Ayman Kabakibi - San Diego CA, US
Assignee:

KALYPSYS, INC. - San Diego CA
International Classification:

A61K 31/497
A61K 31/4709
A61K 31/415
A61K 31/405
US Classification:

514 2, 51425212, 514369, 514381, 514311, 514307, 514419, 546169, 546146, 548253
Abstract:

The present invention is directed to novel compositions and their application as pharmaceuticals for the treatment of disease. Methods of upregulation of GLUT4 via activation of peroxisome proliferator activated receptor delta activity in the adipose tissue of a human or animal subject are also provided, for the treatment of conditions such as diabetes, obesity, insulin resistance, metabolic syndrome, and others in which a reduction in insulin resistance, an increase in glucose utilization, a reduction in visceral fat, a reduction in triglyceride (TG) levels, or an increase in levels of high-density lipoprotein (HDL), is beneficial.

Heterocyclic Modulators Of Tgr5 For Treatment Of Disease
view source
US Patent:

20080221161, Sep 11, 2008
Filed:

Feb 5, 2008
Appl. No.:

12/026315
Inventors:

Anthony B. Pinkerton - San Diego CA, US
Ayman Kabakibi - San Diego CA, US
Mark R. Herbert - San Diego CA, US
Dana Siegel - San Diego CA, US
Assignee:

KALYPSYS, INC. - San Diego CA
International Classification:

A61K 31/4725
C07D 215/00
A61P 3/00
US Classification:

514314, 546177
Abstract:

Disclosed herein are compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.

Quinazolinone Modulators Of Tgr5
view source
US Patent:

20090035306, Feb 5, 2009
Filed:

Nov 20, 2007
Appl. No.:

11/943097
Inventors:

Anthony B. Pinkerton - San Diego CA, US
Ayman Kabakibi - San Diego CA, US
Timothy Z. Hoffman - San Diego CA, US
Dana L. Siegel - San Diego CA, US
Stewart A. Noble - San Diego CA, US
Assignee:

KALYPSYS, INC. - San Diego CA
International Classification:

C07D 239/88
A61K 31/517
C07D 405/04
C07D 409/04
C07D 401/04
A61K 39/395
A61P 3/00
A61P 3/10
A61P 1/00
A61P 19/02
US Classification:

4241331, 544289, 51426631, 51426624, 544284, 51426621
Abstract:

The present invention relates to quinazolinone compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.

Use Of -Linolenic Acid Metabolites For Treatment Or Prevention Of Cancer
view source
US Patent:

6340705, Jan 22, 2002
Filed:

Sep 10, 1999
Appl. No.:

09/393790
Inventors:

Mark Obukowicz - Kirkwood MO
Ayman Kabakibi - Creve Coeur MO
Susan L. Green - St. Ann MO
Lisa M. Olson - Richmond Heights MO
Julie Lindemann - El Cerrito CA
Assignee:

Monsanto Technology, LLC - St. Louis MO
International Classification:

A61K 3120
US Classification:

514560
Abstract:

Cancer in a mammal can be treated or prevented by administering to a mammal in need thereof a cancer inhibiting amount of metabolite(s) of -linolenic acid, such as stearidonic acid (18:4 n-3), eicosatetraenoic acid (20:4 n-3), docosaptentaenic acid (22:5 n-3) and mixtures thereof, especially metabolites including stearidonic acid.

Immunomodulating Polynucleotides, Antibody Conjugates Thereof, And Methods Of Their Use
view source
US Patent:

20180312536, Nov 1, 2018
Filed:

Apr 13, 2018
Appl. No.:

15/953290
Inventors:

- Dublin, IE
Curt W. Bradshaw - San Diego CA, US
Son Lam - San Diego CA, US
Joseph Stock - San Diego CA, US
Edward Hyungsuk Ha - Solana Beach CA, US
Laxman Eltepu - San Diego CA, US
Dingguo Liu - San Diego CA, US
Bin Liu - San Diego CA, US
Giuseppe Dello Iacono - Oceanside CA, US
Bryan R. Meade - San Diego CA, US
Ayman Kabakibi - San Diego CA, US
International Classification:

C07H 21/04
A61K 31/7125
A61K 47/68
C07K 16/28
C07K 7/06
A61P 35/00
A61K 39/00
A61K 39/39
A61K 47/60
Abstract:

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

Polynucleotide Constructs Having Disulfide Groups
view source
US Patent:

20160257961, Sep 8, 2016
Filed:

Nov 6, 2014
Appl. No.:

15/034973
Inventors:

Curt W. BRADSHAW - San Diego CA, US
Laxman ELTEPU - Carlsbad CA, US
Ayman KABAKIBI - San Diego CA, US
Son LAM - San Diego CA, US
Bin LIE - San Diego CA, US
Dingguo LIE - San Diego CA, US
Bryan R. MEADE - San Diego CA, US
Sukumar SAKAMURI - San Diego CA, US
- Dubblin 2, IE
International Classification:

C12N 15/113
Abstract:

The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internucleotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internucleotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internucleotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.